| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $49,541,440 ) (Continued on the next page) |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | ELM & CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R35GM148071 | The Genetic Basis of Human DNA Replication Timing | 001 | 2 | NIH | 12/18/2023 | $412,236 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA243456 | Radiogenomic Credentialing of Head and Neck Cancer Models | 001 | 4 | NIH | 4/15/2024 | $29,087 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | ELM & CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA243456 | Radiogenomic Credentialing of Head and Neck Cancer Models | 000 | 4 | NIH | 11/9/2023 | $523,581 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R37CA248018 | Leveraging the GTP Biosynthetic Pathway for Anti-Tumor Therapies | 001 | 4 | NIH | 4/15/2024 | $19,178 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | ELM & CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R37CA248018 | Leveraging the GTP Biosynthetic Pathway for Anti-Tumor Therapies | 000 | 4 | NIH | 11/8/2023 | $345,207 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA255242 | Advancing skin cancer prevention by tackling UV-induced clonogenic mutations | 001 | 4 | NIH | 4/17/2024 | $29,904 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA255242 | Advancing skin cancer prevention by tackling UV-induced clonogenic mutations | 000 | 4 | NIH | 1/19/2024 | $538,310 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA258337 | Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence | 003 | 3 | NIH | 5/2/2024 | $32,721 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA258337 | Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence | 002 | 3 | NIH | 4/16/2024 | $11,705 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | ELM & CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA258337 | Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence | 001 | 3 | NIH | 12/15/2023 | $210,658 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | ELM & CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R01CA258337 | Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence | 000 | 3 | NIH | 12/1/2023 | $588,984 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA292639 | Targeting retrotransposons for improved treatment of refractory childhood cancer | 000 | 1 | NIH | 6/5/2024 | $602,486 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R21CA286342 | Identifying Chemo-Neoepitopes for Immunotherapy Interventions Against Triple-Negative Breast Cancer | 000 | 1 | NIH | 5/30/2024 | $460,977 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | K08CA279766 | Stress-induced immunosuppression via downregulation of interferon in triple negative breast cancer | 001 | 1 | NIH | 6/3/2024 | $290 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | K08CA279766 | Stress-induced immunosuppression via downregulation of interferon in triple negative breast cancer | 000 | 1 | NIH | 5/31/2024 | $314,043 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA283547 | Interstitial Photodynamic Therapy Following Palliative Radiotherapy for Patients with Inoperable Malignant Central Airway Obstruction | 001 | 1 | NIH | 3/14/2024 | -$29,997 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA283547 | Interstitial Photodynamic Therapy Following Palliative Radiotherapy for Patients with Inoperable Malignant Central Airway Obstruction | 000 | 1 | NIH | 2/26/2024 | $728,484 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R03CA289559 | Linking lifestyles with tumor immune profiles to identify strategies for improving breast cancer outcomes | 000 | 1 | NIH | 3/1/2024 | $86,750 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA283501 | MedSupport: A Novel Multilevel Intervention to Identify and Address Barriers to Pediatric Medication | 000 | 1 | NIH | 3/15/2024 | $754,264 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R21CA288931 | Combined inhibition of ATR and p110β as Therapy in PTEN-deficient Prostate Cancer | 000 | 1 | NIH | 2/22/2024 | $202,778 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R37CA275961 | Targeting HNF1A-mediated therapeutic resistance in pancreatic ductal adenocarcinoma | 001 | 2 | NIH | 4/17/2024 | $23,664 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | ELM & CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R37CA275961 | Targeting HNF1A-mediated therapeutic resistance in pancreatic ductal adenocarcinoma | 000 | 2 | NIH | 1/9/2024 | $425,943 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | F30CA284763 | Understanding the role of β2AR-signaling on ILC2 differentiation/plasticity and its implications in cancer progression | 000 | 2 | NIH | 8/7/2024 | $33,792 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA278802 | TLR5 enhancement of liver-directed radiotherapy plus immune checkpoint blockade against irradiated liver metastasis and abscopal tumors | 000 | 2 | NIH | 4/30/2024 | $677,410 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R37CA282430 | Novel synthetic lethality strategy for TP53 mutant colorectal cancer | 000 | 2 | NIH | 8/1/2024 | $502,520 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA272771 | The role of USP27X-Cyclin D1 axis in HER2 Therapy Resistant Breast Cancer | 001 | 2 | NIH | 4/17/2024 | $21,699 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA272771 | The role of USP27X-Cyclin D1 axis in HER2 Therapy Resistant Breast Cancer | 000 | 2 | NIH | 3/5/2024 | $390,585 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01HL167232 | Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantation | 002 | 2 | NIH | 7/31/2024 | -$14,471 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01HL167232 | Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantation | 001 | 2 | NIH | 4/25/2024 | $723,500 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R03CA280307 | The role of ceramide kinase in metastasis growth from aggressive breast cancer | 000 | 2 | NIH | 4/16/2024 | $86,750 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA281862 | A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors | 000 | 2 | NIH | 8/12/2024 | $735,428 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01DA057228 | Assessing pharmacokinetic and pharmacodynamic variability of Δ9-tetrahydrocannabinol delivered from vaping products with and without concurrent use of nicotine | 001 | 3 | NIH | 6/21/2024 | $666,413 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01MD016850 | Implementation of evidence-based strategies to optimize HPV vaccination in rural primary care settings | 000 | 3 | NIH | 5/1/2024 | $665,986 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R00HL155792 | Implication of Galectin-3 to regulate Graft vs. Host Disease (GvHD) and Graft vs. Tumor (GVT) Responses | 000 | 5 | NIH | 5/29/2024 | $249,000 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA257480 | Transcriptomic classification of non-muscle invasive bladder cancer and its clinical and prognostic implication | 000 | 3 | NIH | 8/13/2024 | $1,256,124 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | U24CA274159 | Coordinating and Data Management Center for Acquired Resistance to Therapy Network | 007 | 3 | NIH | 9/25/2024 | $986,818 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | U24CA274159 | Coordinating and Data Management Center for Acquired Resistance to Therapy Network | 007 | 3 | NIH | 9/25/2024 | -$986,818 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA267690 | Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer | 000 | 3 | NIH | 7/19/2024 | $618,854 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | U24CA274159 | Coordinating and Data Management Center for Acquired Resistance to Therapy Network | 006 | 3 | NIH | 9/17/2024 | -$986,818 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | U24CA274159 | Coordinating and Data Management Center for Acquired Resistance to Therapy Network | 006 | 3 | NIH | 9/17/2024 | $986,818 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | U24CA274159 | Coordinating and Data Management Center for Acquired Resistance to Therapy Network | 003 | 3 | NIH | 8/31/2024 | $758,183 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | U24CA274159 | Coordinating and Data Management Center for Acquired Resistance to Therapy Network | 004 | 3 | NIH | 9/6/2024 | -$758,183 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | U24CA274159 | Coordinating and Data Management Center for Acquired Resistance to Therapy Network | 005 | 3 | NIH | 9/6/2024 | $0 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | U24CA274159 | Coordinating and Data Management Center for Acquired Resistance to Therapy Network | 002 | 3 | NIH | 8/29/2024 | $1,745,001 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R50CA283761 | Development of New Technologies at Roswell Park to Further Cancer-Based Research and Treatment Through Genome Modification | 000 | 2 | NIH | 8/30/2024 | $324,868 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | F31CA288029 | Examining the impact of laboratory housing temperature on murine CD28 and the response to anti-PD-1 | 000 | 2 | NIH | 8/16/2024 | $36,792 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA262822 | Role of type 2 immune response in pancreatic cancer tumorigenesis | 001 | 4 | NIH | 7/18/2024 | $59,672 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA262822 | Role of type 2 immune response in pancreatic cancer tumorigenesis | 002 | 4 | NIH | 8/7/2024 | -$713 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA262822 | Role of type 2 immune response in pancreatic cancer tumorigenesis | 000 | 4 | NIH | 6/25/2024 | $388,432 |
|
| Loading… |
|
